Azenta, Inc.

AZTA · 8-K · Filed Oct 7 · 12:010001628280-26-065292Read the filing ›Open on SEC EDGAR

8-K

azta-20261005.htm

Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.05. Costs Associated with Exit or Disposal Activities .

¶1

On October 5, 2026, the Board of Directors of Azenta, Inc. (the “Company”) approved, and the Company committed to, a restructuring plan (the “Plan”) within the Company’s Multiomics reportable segment. The Plan is intended primarily to consolidate the Company’s North American laboratory network, simplify its organizational structure and improve operating efficiency, and consists of workforce reductions and the closure of three of the Company’s Multiomics laboratory sites in North America. The Company began notifying affected employees of the actions contemplated by the Plan on October 6, 2026.

¶2

The Company currently estimates that it will incur aggregate pre-tax charges of approximately $11.0 million to $13.0 million in connection with the Plan, consisting primarily of approximately $9.0 million of asset impairment charges described under Item 2.06 below and approximately $3.0 million of employee severance and other restructuring charges. The Company currently estimates that the aggregate future cash expenditures associated with these charges will be approximately $7.0 million.